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CASE-LETTER
Pathological Fracture Caused by
Vascular Endothelial Cell
Hemangioma-like Hyperplasia in
POEMS Syndrome
POEMS syndrome is a rare paraneoplastic syndrome second-ary to plasma cell dyscrasia.
Osteosclerotic bone lesion is a characteristic change seen
in POEMS syndrome, whereas pathological fracture is rare.
Monoclonal l plasmacytoma may be the main pathological
change responsible for bone lesions in patients with POEMS
syndrome.1 In this study, we describe a patient who presented
with a pathological fracture. Bone pathology indicated
hemangioma-like vascular endothelial cell hyperplasia. To the
best of our knowledge, this is the second report of pathological
fracture caused by POEMS syndrome and the ﬁrst report of
pathological fracture caused by hemangioendothelioma-like
changes in a patient with POEMS syndrome.
A 55-year-old woman was hospitalized in August 2013 for
severe pain in her left leg. An x-ray revealed a pathological
fracture with an osteolytic lesion on the distal left femur and
a sclerotic lesion on the proximal right femur (Figure 1A). Spleno-
megaly, ascites, skin hyperpigmentation and hemangiomas,
multiple enlarged lymph nodes and elevated serum creatinine
(228 mmol/L, normal range, 70–110 mmol/L) were found. Serum
immunoglobulin assay yielded the following results: immuno-
globulin A (IgA), 2.23 g/L (normal range, 0.82–4.53 g/L); IgG,
9.63 g/L (normal range, 7.51–15.6 g/L) and IgM, 1.37 g/L (nor-
mal range, 0.4–2.74 g/L). The monoclonal M-protein (IgA, l)
was detected on serum immunoﬁxation, but not through serum
electrophoresis and urine immunoﬁxation. Endocrine investiga-
tions revealed an increase in thyroid-stimulating hormone (11.9
mIU/L, normal range, 0.34–5.6 mIU/L) and a decrease in free
triiodothyronine (3.38 pmol/L, normal range, 4.36–6.23 pmol/L).
Bone marrow biopsy and aspiration were negative for plasma
cells. The patient exhibited no symptoms of peripheral neuropa-
thy, but electromyography examination showed symmetric
peripheral nerve defects in both lower extremities. Pathology of
lymph nodes indicated hyaline-vascular type Castleman’s disease
(CD). Biopsy of the distal left femur revealed dramatic
glomeruloid-like vascular endothelial cell hyperplasia, which
was similar to the pathological changes observed in hemangiomas
(Figure 1; panels B1, B2 and B3). No plasmacyte inﬁltration was
found. Immunohistochemical ﬁndings were positive for the pres-
ence of human soluble adhesion molecules (SMA), CD34 and
negative for CD38 and CD138. Kidney pathology showed diffuse
mesangial cell and capillary proliferation in the glomerulus, with
eosinophilic material deposits. Plasma vascular endothelial
growth factor (VEGF) was higher than normal (898 pg/mL, nor-
mal level ,145 pg/mL). POEMS syndrome was diagnosed. In-
terlocking intramedullary nail internal ﬁxation of the fracture was
performed and chemotherapy was given (lenalidomide, 15 mg/d,
days 1–21; dexamethasone, 40 mg, once weekly in a 28-day
FIGURE 1. Imaging and pa-
thology. (A) X-ray of the bilateral
femurs revealed a pathological
fracture with an osteolytic lesion
on the distal left femur and
a sclerotic lesion on the proximal
right femur (arrowhead). (B1)
Dramatic endothelial cell pro-
liferation with labyrinth-like ves-
sel lumen formation was
revealed in this biopsy of the
distal left femur, which showed
similar characteristics to glo-
meruloid hemangioma (hema-
toxylin and eosin staining,
3200). Immunohistochemical
study demonstrated positive
expression of CD34 (B2, 3200)
and SMA (B3, 3200).
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cycle). The patient also received radiation treatment (4000 cGy).
At the 14-month follow-up, the patient had no signs of pain or
ascites.
The great diversity of POEMS syndrome clinical features
can easily lead to misdiagnosis.
Although bone lesions, which are characterized by
sclerotic or osteolysis damage with a sclerotic edge, are seen
in more than 90% of patients with POEMS syndrome, most
patients do not have symptoms of bone pain and fracture is
rare.2 Livingston et al3 reported the ﬁrst case of pathological
fracture caused by POEMS syndrome. To the best of our
knowledge, our present report is only the second description
of pathological fracture in a patient with POEMS syndrome.
Pathological fracture is a rare complication in POEMS
syndrome. Plasmacytoma may be the major pathological change
responsible for bone lesions in POEMS syndrome, as studies of
bone lesion pathology show that more than 95% of patients with
POEMS syndrome have monoclonal l plasmacytoma.4 In this
case, the patient exhibited a pathological fracture caused by
hyperplastic vascular endothelium, similar to the pathologic
changes observed in hemangioendothelioma. Although the
M-protein might be a driving factor in POEMS syndrome
pathogenesis, VEGF also reportedly plays important etiological
roles.2,5 VEGF is the dominant cytokine in the regulation of
endothelial cell proliferation, migration and permeability.
Elevated VEGF is considered to be responsible for several
characteristic symptoms of POEMS syndrome, including extra-
vascular volume overload, hemangioma and papilledema.2
Higher VEGF levels may stimulate vascular endothelial cell
proliferation in the bone to form a labyrinth-like vessel lumen,
causing bone destruction or pathological fracture. It is currently
unknown whether bone lesions occur due to plasmacytoma or
whether they occur secondary to the elevated VEGF level.
In this case, the biopsy showed only hyperplastic
vascular endothelium, with no evidence of plasma inﬁltration,
suggesting that the hemangioendothelioma-like change may
have been the major cause of the bone lesion. To the best of our
knowledge, this is the ﬁrst report of pathological fracture caused
by a hemangioendothelioma-like change in POEMS syndrome.
The patient also displayed capillary proliferation in the affected
lymph nodes and kidney. Similar pathological changes have
been reported in biopsies of patients with POEMS syndrome
combined with CD.2 It is possible that capillary proliferation is
a pathological change common among all affected organs in
patients with POEMS syndrome combined with CD; however,
conﬁrmation of this hypothesis requires additional investiga-
tion. To better understand the pathology of bone lesions in
POEMS syndrome, further pathogenetic and histopathological
analyses are needed.
The treatment for POEMS syndrome is based on the
extent of the plasma cell inﬁltration and the number of bone
lesions.1 For patients with solitary or limited bone lesions (#3
bone lesions) without diffuse plasma cell lesions, radiation is
the ﬁrst-line therapy.6 In cases with disseminated bone marrow
involvement, systemic therapy is indicated.4 There are no stan-
dard recommended therapy protocols for the treatment of
POEMS syndrome. Recent studies indicated that lenalidomide
was a promising drug for its direct antimyeloma, anti-VEGF
effects and much lower risk for peripheral neuropathy.7 Con-
sidering that the patient’s tumor was massive and that there was
multiple organ involvement, local irradiation was performed in
combination with chemotherapy. Although evaluation of the
long-term outcome for this patient will need an extended obser-
vation period, an excellent short-term result was achieved.
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